Ibrahim Turkoz, Cynthia A Bossie, Bryan Dirks, Carla M CanusoOrtho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USAAbstract: Direct and indirect effects of the new psychotropic paliperidone extended-release (paliperidone ER) tablets on negative symptom improv... View more
Andreasen NC. 1982. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry, 39:784-8.
Ayuso-Gutierrez JL, del Rio Vega JM. 1997. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res, 28:199-206.
Barnes TR. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry, 154:672-6.
Carpenter WT Jr, Heinrichs DW, et al. 1985. Treatment of negative symptoms. Schizophr Bull, 11:440-52.
Davidson L, McGlashan TH. 1997. The varied outcomes of schizophrenia. Can J Psychiatry, 42:34-43.
Davidson M, Emsley R, Kramer M, et al. 2007. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res, 93:117-30.
Docherty JP, Grogg AL, Kozman C, et al. 2002. Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. American College of Neuropsychopharmacology 41st Annual Meeting; San Juan, Puerto Rico. December 8-12.
Gharabawi G, Bossie C, Turkoz I, et al. 2007. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. J Nerv Mental Dis, 195:976-82.
Guy WA. 1972. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education and Welfare. p. 533-7.
Guy WA. 1976. Clinical global impressions. In: ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education and Welfare. p. 218-222.